Loading...
Although androgen-deprivation therapy (ADT) has been the standard of care for men with metastatic prostate cancer for more than 60 years, ADT has been prescribed increasingly for nonmetastatic disease during the past 10 to 15 years. Some uses are supported by prospective evidence (e.g., ADT in combination with radiotherapy for locally advanced disease), but much of the increased use falls into the category of “early” ADT in men with locally advanced disease or rising prostate-specific antigen (PSA) levels — a clinical practice that is not supported by prospective evidence. Investigators have shown previously that the percentage of total variance in the use of ADT that is attributable to individual urologists’ prescribing patterns is consist…